In a phase II trial of 128 adults with AML or ALL having unrelated or haploidentical transplant, PTCy-ruxolitinib was non-inferior to PTCy-tacrolimus-MMF for grade II-IV acute GVHD at 125 days (12.9% vs 21.2%), with less kidney injury; survival did not differ.
RCTn = 128
Moiseev et al. A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide